An observational study in Eosinophilic Disorder, Eosinophilic Esophagitis (EoE) and Eosinophilic Disease, sponsored by Medical University of Warsaw. Completed at 1 site in Poland. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Medical University of Warsaw · Observational
The aim of the study is to assess the incidence of EZP in Poland in the pediatric population and characteristics of Polish patients with EZP, i.e. their demographic, clinical, endoscopic and histological features. Another important objective of the study is to identify areas where the diagnosis and treatment of EZP in children can be improved. The study is prospective and non-interventional.
Data will be collected in the REDCap (Research Electronic Data Capture) platform, which ensures the security of collected data and widely used in international clinical trials.
All centers performing endoscopic examinations in children in Poland will be invited to participate in the study. One person from each center will be designated to collect data and update the database.
The data entered will be regularly updated with the results of follow-up examinations and the effects of treatment of patients by a designated person at the center. The data entered will only include data collected during routine clinical practice. The registry will not contain any data enabling the identification of patients, e.g., home address. Inclusion of data in the registry will not pose any health risks and does not require any tests other than routine ones.
Participation in the registry is voluntary and requires the written consent of the parent/legal guardian and/or patient. Participation may be refused without giving a reason, without affecting the patient's treatment. Consent may be changed or withdrawn at any time.
The attending physician will inform the patient and parent/legal guardian about the database and explain its value and benefits as well as the rights of participants. In addition, each participant will be provided with an information brochure about the registry.
235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.
This study's enrollment of 250 is above the median of 88 across 85 observational studies indexed under Eosinophilic Esophagitis.
Browse Eosinophilic Esophagitis studies →Medical University of Warsaw is the lead sponsor of 326 studies on the registry; 87 are open to participants now.
Compared within Eosinophilic Esophagitis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Eosinophilia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
ddd
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients from all over Poland with newly diagnosed eosinophilic esophagitis aged 0 to 18 will be included in the registry, initially from 1 June 2024, to 31 May 2025, and then until 31 May 31 2026.
Other: Data collection
Patient data will include information collected during routine clinical practice, e.g., body weight, height, EZP symptoms, allergy symptoms, laboratory test results, endoscopy results, etc. Entering data into the registry will not pose any health risks and does not require any tests beyond routine ones.
Characteristics of Polish pediatric patients
Characteristics of Polish patients with EZP, f.e., their demographic, clinical, endoscopic and histological features.
Time frame: June 2024 - May 2026
Incidence of EoE in children in Poland.
Assessment of the incidence of EZP in Poland in the pediatric population.
Time frame: June 2024 - May 2026
Improving the efficiency of proposed diagnostic and therapeutic protocols
Identification of areas where the diagnosis and treatment of EZP in children can be improved.
Time frame: June 2024 - May 2026
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in May 2025, 11 months.
Of 52 non-industry observational studies under Eosinophilic Esophagitis, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 120. This study's 11 months is below that.
Counting every sponsor, half of 55 studies reached it within 49 months; a quarter within 22 and three quarters within 120.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Warsaw →